PARP in colorectal cancer: Molecular mechanisms, immunity, clinical trials, and drug combinations

被引：8
作者：
Wu, Fa-Hong [1 ]
Wei, Hang-Zhi [1 ]
Deng, Hong-Yang [1 ]
Xiao, Guo-Hui [1 ]
Zhang, You-Cheng [1 ]
机构：
[1] Lanzhou Univ, Hosp 2, Hepatobiliarypancreat Inst, Dept Gen Surg, Lanzhou, Gansu, Peoples R China
来源：
NEOPLASMA | 2023年 / 70卷 / 01期
关键词：
PARP; colorectal cancer; DNA damage; immunity; clinical trial; REGULATES PD-L1 EXPRESSION; DNA-REPAIR; OVARIAN-CANCER; INHIBITION; CELLS; OLAPARIB; PATHWAY; SUPPRESSES; SENSITIZES; RESISTANCE;
D O I：
10.4149/neo_2022_220724N745
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The changes in cell homeostasis in the tumor microenvironment may affect the development of colorectal cancer (CRC). Genomic instability is an important factor. Persistent genomic instability leads to epigenetic changes, and mutations are a major factor in the progression of CRC. Based on these mechanisms, it is reasonable to link poly (ADP-ribose) polymerase (PARP) with the treatment of CRC. PARP is mainly involved in DNA repair, which has an essential role in the DNA damage response and prevention of DNA damage, and maintains oxidation and superoxide redox homeostasis in the intracellular environment of the tumor. This article reviews the latest research progress on PARP and PARP inhibi-tors (PARPi) in CRC. It mainly includes molecular mechanisms, immunity, clinical trials, and combination strategies of CRC. The research of PARPi in CRC has broad prospects, and the combinations with other drugs are the main research direction in the future.
引用
收藏
页码：1 / 14
页数：14
相关论文
共 112 条
[41]   CXCL16 suppresses liver metastasis of colorectal cancer by promoting TNF-α-induced apoptosis by tumor-associated macrophages [J].
Kee, Ji-Ye ;
Ito, Aya ;
Hojo, Shozo ;
Hashimoto, Isaya ;
Igarashi, Yoshiko ;
Tsuneyama, Koichi ;
Tsukada, Kazuhiro ;
Irimura, Tatsuro ;
Shibahara, Naotoshi ;
Takasaki, Ichiro ;
Inujima, Akiko ;
Nakayama, Takashi ;
Yoshie, Osamu ;
Sakurai, Hiroaki ;
Saiki, Ikuo ;
Koizumi, Keiichi .
BMC CANCER, 2014, 14
[42]   Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003 [J].
Kim, Tae Won ;
Taieb, Julien ;
Gurary, Ellen B. ;
Lerman, Nati ;
Cui, Karen ;
Yoshino, Takayuki .
FUTURE ONCOLOGY, 2021, 17 (36) :5013-5022
[43]   CD28 AND CTLA-4 HAVE OPPOSING EFFECTS ON THE RESPONSE OF T-CELLS TO STIMULATION [J].
KRUMMEL, MF ;
ALLISON, JP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (02) :459-465
[44]   Low dose novel PARP-PI3K inhibition via nanoformulation improves colorectal cancer immunoradiotherapy [J].
Landry, M. R. ;
DuRoss, A. N. ;
Neufeld, M. J. ;
Hahn, L. ;
Sahay, G. ;
Luxenhofer, R. ;
Sun, C. .
MATERIALS TODAY BIO, 2020, 8
[45]   Fuzuloparib: First Approval [J].
Lee, Arnold .
DRUGS, 2021, 81 (10) :1221-1226
[46]   Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer [J].
Leichman, Lawrence ;
Groshen, Susan ;
O'Neil, Bert H. ;
Messersmith, Wells ;
Berlin, Jordan ;
Chan, Emily ;
Leichman, Cynthia G. ;
Cohen, Steven J. ;
Cohen, Deirdre ;
Lenz, Heinz-Josef ;
Gold, Philip ;
Boman, Bruce ;
Fielding, Anitra ;
Locker, Gershon ;
Cason, Ronald C. ;
Hamilton, Stan R. ;
Hochster, Howard S. .
ONCOLOGIST, 2016, 21 (02) :172-177
[47]   PARP inhibitors: Synthetic lethality in the clinic [J].
Lord, Christopher J. ;
Ashworth, Alan .
SCIENCE, 2017, 355 (6330) :1152-1158
[48]   Mechanisms of resistance to therapies targeting BRCA-mutant cancers [J].
Lord, Christopher J. ;
Ashworth, Alan .
NATURE MEDICINE, 2013, 19 (11) :1381-1388
[49]  
Lu HY, 2019, CURR TOP MED CHEM, V19, P1041, DOI [10.2174/15680266119666190603092407, 10.2174/1568026619666190603092407]
[50]   NAMPT Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP [J].
Lucena-Cacace, Antonio ;
Otero-Albiol, Daniel ;
Jimenez-Garcia, Manuel P. ;
Munoz-Galvan, Sandra ;
Carnero, Amancio .
CLINICAL CANCER RESEARCH, 2018, 24 (05) :1202-1215
12345678910